Aerolase
- Company typePrivate
- Founded1996
- HeadquartersTarrytown, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Aerolase firmographics
Firmographics- Name
- Aerolase
- Legal name
- Aerolase
- Website
- https://aerolase.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Aerolase industry classification
Industry- Product category
- Medical Aesthetic Lasers
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Laser & Energy-Based Dermatology (HLAKACAF)
- akta.pro secondary industries
- General & Medical Dermatology (HLAKACAA), Psoriasis & Eczema Specialty Care (HLAKACAL), Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE)
Keywords
Where Aerolase is headquartered
LocationHeadquarters
- HQ city
- Tarrytown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aerolase business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Infrastructure
Revenue model
- Laser Device Sales: Aerolase generates primary revenue from selling medical laser devices (Neo Elite, Era Elite, Exci308). Practices purchase the capital equipment outright. The ROI is achieved within 6-12 months based on per-treatment revenue generation. Devices treat 36+ FDA-cleared indications enabling multiple revenue streams from single device investment.
- Treatment Revenue for Practices: Practices generate revenue through per-session treatments priced at $200-400 per acne treatment session. Patients typically require 4-6 treatments, generating $2,400-$3,600 per patient for a single condition. Practices can see 4-6 patients per hour with 10-15 minute treatments, enabling 200+ monthly treatments vs competitors' 80-120.
- No Consumable Revenue Model: Unlike competitors requiring filter changes, cooling calibration, and consumable costs, Aerolase's no-consumables model eliminates ongoing per-treatment costs for practices. This creates favorable practice economics and lower total cost of ownership, though it means Aerolase does not capture consumable revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Neo Elite - 650-microsecond Nd:YAG for 36+ FDA-cleared indications |
| One time/ perpetual license | Pay-as-you-go | Era Elite - 300-microsecond Er:YAG for skin resurfacing |
| One time/ perpetual license | Pay-as-you-go | Exci308 - 308nm Excimer for psoriasis and vitiligo |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels9 records
Aerolase product offering
Product offeringCore offering
Aerolase designs, manufactures, and sells FDA-cleared medical laser platforms for dermatology and aesthetic practices. Its core products are the Neo Elite (650-microsecond Nd:YAG laser for 36+ indications including acne, rosacea, melasma, and vascular lesions), the Era Elite (300-microsecond Er:YAG laser for skin resurfacing), and the Exci308 (308nm excimer laser for psoriasis and vitiligo). Devices are sold primarily as one-time capital purchases to dermatologists, medical spas, plastic surgeons, and aesthetic practices globally, with no consumable or cooling requirements.
Product overview
Aerolase offers a portfolio of advanced medical laser platforms built around proprietary ultra-short pulse technology (650-microsecond Nd:YAG and 300-microsecond Er:YAG). The core product lineup includes Neo Elite for non-ablative treatments across 36+ indications, Era Elite for ablative skin resurfacing, and Exci308 for narrowband UVB treatment of autoimmune skin conditions. These devices share common technology foundations (ultra-short pulse durations, air-cooled design) and are often combined in clinical protocols like the Reverse treatment approach. All platforms are FDA-cleared, safe for all Fitzpatrick skin types, and require no consumables or cooling systems.
Differentiator
Problem solved
Functional benefit
Brands
- Neo Elite: Primary Nd:YAG laser platform with 650-microsecond technology for treating acne, rosacea, pigmentation, and other dermatological conditions
- Era Elite
- Exci308
Products and services
- Neo Elite Aerolase's primary Nd:YAG 1064nm laser platform featuring proprietary 650-microsecond pulse technology, FDA-cleared for 36+ indications including acne, rosacea, pseudofolliculitis barbae, melasma, pigmentation, vascular lesions, and skin rejuvenation. Safe for all Fitzpatrick skin types (I-VI) with no downtime, no cooling, and no consumables.
- Era Elite Aerolase's Er:YAG 2940nm laser with proprietary 300-microsecond pulse technology for ablative skin resurfacing. Treats wrinkles, scars, skin texture, and rejuvenation concerns. Safe for darker Fitzpatrick skin types (IV-VI) that were previously contraindicated for ablative laser treatments. Often combined with Neo Elite for comprehensive skin health protocols.
- Exci308 A 308nm excimer laser system delivering targeted narrowband UVB therapy for autoimmune and inflammatory skin conditions including psoriasis, vitiligo, atopic dermatitis, and eczema. Targets scalp and localized treatment areas with insurance reimbursement potential.
- Reverse by Aerolase A treatment protocol combining the Neo Elite and Era Elite laser devices to provide corrective and preventive anti-aging skin treatment. Designed for patients 25+ seeking comprehensive skin rejuvenation across multiple signs of aging.
Quantifiable outcome
- 87% average clearance across treated conditions (acne, rosacea, pigmentation)
- +8 more outcomes
Companies that use Aerolase
Customer profileNamed customers8 records
Segments6 records
Ideal customer profiles4 records
Aerolase technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Aerolase partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Kaya ClinicscoreAerolase launched its Neo Elite laser technology in India in partnership with Kaya Clinics in August 2025. The partnership makes the US FDA-cleared 650-microsecond laser device available across Kaya's nationwide clinic network. Kaya Clinics is a leading dermatology chain in India, and the partnership aims to establish new benchmarks for skin health solutions in India's B2B dermatology sector. The collaboration targets India's rapidly evolving aesthetics market with over 36 dermatological and aesthetic indications.
Scale indicators6 records
Recent moves6 records
Expansion highlights3 records
Aerolase competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Aerolase social profiles
Digital presenceAerolase financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aerolase leadership team
Management profileNumber of profiles
Profiles2 records
Aerolase funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aerolase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aerolase
What does Aerolase do?
Aerolase designs, manufactures, and sells FDA-cleared medical laser platforms for dermatology and aesthetic practices. Its core products are the Neo Elite (650-microsecond Nd:YAG laser for 36+ indications including acne, rosacea, melasma, and vascular lesions), the Era Elite (300-microsecond Er:YAG laser for skin resurfacing), and the Exci308 (308nm excimer laser for psoriasis and vitiligo). Devices are sold primarily as one-time capital purchases to dermatologists, medical spas, plastic surgeons, and aesthetic practices globally, with no consumable or cooling requirements.
Is Aerolase a public or private company?
Aerolase is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aerolase founded?
Aerolase was founded in 1996. It employs 11 to 50 people.
Where is Aerolase based?
Aerolase is headquartered in Tarrytown, United States, in the North America region.
How does Aerolase make money?
Three revenue lines are on record. Laser Device Sales are the primary driver. The others are treatment Revenue for Practices and no Consumable Revenue Model.
Does Aerolase have an API?
No public API is recorded for Aerolase.
What industry is Aerolase in?
Aerolase's product category is Medical Aesthetic Lasers. Its primary akta.pro industry code is HLAKACAF, Laser & Energy-Based Dermatology, with a secondary code of HLAKACAA, General & Medical Dermatology. Its NAICS code is 334510 and its SIC code is 3841.